Novartis beats consensus on Q4 earnings
Novartis on Friday posted quarterly adjusted net income well above analyst estimates on higher drug revenues.
Novartis to Report Q4 Earnings: What's in the Offing?
NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.
US appeals court lifts pause on generic version of Novartis' Entresto
Drugmaker MSN Pharmaceuticals cleared another hurdle on Thursday toward launching its generic version of Novartis' blockbuster heart-failure drug Entresto after a U.S. appeals court ended a temporary pause on MSN's launch.
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet AMD) patients.
Novartis loses emergency bid to block Entresto generic in US
A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug Entresto.
Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Novartis AG (NYSE:NVS ) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Vas Narasimhan - Chief Executive Officer Conference Call Participants Richard Vosser - J.P.
Novartis CEO: We need to get Europe to pay its fair share
Novartis CEO Vas Narasimhan discusses the pricing of drugs in the U.S. compared to other countries.
Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line
CNBC's Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more.
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite BioAge's clinical setback, its substantial cash position and Novartis deal offer potential for a strategic pivot towards neuroinflammation and age-related conditions. Novartis benefits from BioAge's longevity data, potentially enhancing its neuroscience pipeline and mitigating revenue risks from upcoming loss of exclusivity on key drugs.
Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
Novartis experienced a strong bull run in 2024 but saw a 13% pullback post-Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 patent expirations for key drugs like Entresto, Promacta, and Tasigna triggered a sell-off. Novartis' robust pipeline and new product launches are expected to offset losses from patent expirations, supporting long-term growth and a "Buy" rating.
AI, vaccine distrust, & the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan.
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
